Eli Lilly is reportedly in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, with a deal potentially announced as soon as Monday. The transaction would be a meaningful biotech M&A move for Lilly, though the talks could still collapse. The reported price tag signals continued strategic interest in expanding its healthcare and biotech pipeline.
Eli Lilly is reportedly in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, with a deal potentially announced as soon as Monday. The transaction would be a meaningful biotech M&A move for Lilly, though the talks could still collapse. The reported price tag signals continued strategic interest in expanding its healthcare and biotech pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
